Legend Biotech Corporation
LEGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 120% | 143.7% | 70% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 62.6% | 49.4% | 44.1% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -48.3% | -154.1% | -389.4% | -570% |
| Other Income/Exp. Net | $0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$1 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | -$0 | -$1 | -$0 | -$0 |
| % Margin | -28.2% | -181.8% | -381.5% | -586.4% |
| EPS | -1.94 | -5.88 | -5.62 | -5.48 |
| % Growth | 67% | -4.6% | -2.6% | – |
| EPS Diluted | -1.94 | -5.88 | -5.62 | -5.48 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -18% | -167.6% | -356% | -570.1% |